Higher tamoxifen use as chemoprophylaxis in patients with ductal carcinoma in situ (DCIS) in the last decade.

• DOI: 10.1200/jco.2012.30.27_suppl.191
• Publication Date: 2017-02-24T11:17:03Z
• Authors: Erin E. Roesch; Lai Wei; Bhuvaneswari Rama...
• Keywords: Chemoprophylaxis

191 Background: The incidence of DCIS over the last two decades has increased, with 62,000 new cases diagnosed annually in United States. Tailored management is still a work progress and currently treatment options are varied. We sought to identify changes patterns care individual physician choices for surgery chemoprophylaxis at our institution. Methods: performed retrospective chart review identified 773 eligible patients using James Cancer Registry NCCN database Ohio State University between 1990 2010. compared proportion undergoing mastectomy vs breast conserving (BCT), use radiation hormone therapy, recurrence rates years 1990-2000 2001-2010 Chi-square test. Results: There was no significant difference race (p=0.21) or age (p=0.09) among (Group A, N=462) B, N=311). groups (31% vs. 27%, p= 0.26). Patients less than 50 old were more likely undergo both (p=0.02). Use therapy following BCT similar (52% 53%, p=0.76). Interestingly received during (48% 26%, p < 0.0001). receive (2% 74%, p<0.0001) (25% 39%, p<0.0001). correlation type surgery. process comparing which will be reported. Conclusions: Previously published studies have reported higher early stage cancer recent years. Data from institution did not corroborate this finding, although interestingly we found increasing tamoxifen second decade. Understanding current practices helpful designing future novel prognostic assays such as Oncotype Dx assay.